Mito-LND

Overview

Mito-LND (Mito-Lonidamine) is an orally active and mitochondria-targeted inhibitor of oxidative phosphorylation (OXPHOS) . Mito-LND inhibits mitochondrial bioenergetics, stimulates the formation of reactive oxygen species , and induces autophagic cell death in lung cancer cells.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Digestive System Inflammation | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Autophagy | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Oxidative Phosphorylation | Products > Signaling Pathways > Mitochondrial Metabolism | Products > Signaling Pathways > Reactive Oxygen Species (ROS) | Products > Signaling Pathways > Autophagy

Product Information

• Catalog No.: HY-134832
• CAS No.: 2361564-49-8
• Molecular Formula: C43H45BrCl2N3OP
• Molecular Weight: 801.62
• Purity: 97.0%
• Storage: -20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: ≥ 2.5 mg/mL (3.12 mM); Clear solution
• Availability: In-stock

Source

Original product source